4 ASX shares to buy this week: experts

Looking for investment inspiration?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX All Ordinaries Index (ASX: XAO) is down 0.2% to 8,945.6 points at the time of writing on Tuesday.

Here are four ASX shares attracting buy ratings from the experts this week.

Man smiling at a laptop because of a rising share price.

Image source: Getty Images

4 ASX shares with price growth ahead: brokers

Virgin Australia Holdings Ltd (ASX: VGN)

The Virgin Australia share price is $3.27, up 2.51% on Tuesday.

Ord Minnett has initiated coverage on Virgin Australia with a buy recommendation and a 12-month share price target of $3.65.

Virgin shares had their IPO just recently, returning to the ASX boards on 24 June. The IPO price was $2.90.

So far, the highest level that this ASX airline share has traded at is $3.41 (on its third day of trading).

In a new note, Ord Minnett said it believed Virgin could grow unit revenue at a faster rate than inflation due to weak oil prices and a structurally lower cost base post its administration.

The broker commented:

Virgin is well-placed in terms of fleet renewal requirements, its aircraft having an average age of 13 years, versus 16 years for arch-rival Qantas Airways (QAN) and a typical commercial aircraft life span of around 24 years.

It also has sufficient balance sheet capacity to fund any new aircraft and expansion.

Our expectation is for capital expenditure of $800–900 million over FY26–FY28 that would drive growth in seat numbers of 3% per annum.

Mesoblast Ltd (ASX: MSB)

Mesoblast shares are $2.52, up 1% today.

Bell Potter has maintained a speculative buy rating on this ASX biotech share and raised its 12-month price target from $3.40 to $3.50.

The change followed Mesoblast's latest cashflow update, which revealed US$13.2 million in gross sales for its flagship drug, Ryoncil.

Bell Potter said:

The major catalysts include revenue expansion from Ryoncil and the unrecognised value of a likely Accelerated Approval for Revascor in late-stage heart failure in CY26.

Catalyst Metals Ltd (ASX: CYL)

ASX gold share Catalyst Metals led the 5 best-performing All Ords stocks of FY25 with astounding share price growth of 362%.

Today, the ASX small-cap share is down 0.63% to $4.71.

In a new note, Morgans has upgraded Catalyst from an accumulate rating to a buy rating.

The broker said it has trimmed its 12-month share price target from $7.15 to $6.93 due to unit cost adjustments.

Ahead of the June quarter results we update our model to account for the recent Old Highway acquisition as well as adjustments to quarterly and FY26 forecasts.

With the majority of ASX gold producers reporting unit costs to the upper end of our forecasts, we adjust our cost estimates to reflect the broader upward trend across the gold space.

Regal Partners Ltd (ASX: RPL)

The Regal Partners share price is up 0.5% to $3.04.

Morgans has retained its buy rating on this ASX financial share with a price target of $3.55 after an update from the company.

In this note we update our earnings estimates to reflect updated 1HCY25 performance fees, 1HCY25 NPAT guidance of $40m and continued FUM growth through the Jun-25 quarter.

Trading at a PER of 13x (CY26), with a strong balance sheet and capacity to continue growing FUM, we retain our BUY rating with a price target of $3.55/sh.

Motley Fool contributor Bronwyn Allen has positions in Mesoblast. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a couple consider the advice from a man with documents laid out on a table and the man holding a tablet in his hand.
Financial Shares

3 ASX 200 financial shares to sell: experts

ASX 200 financial shares are down 2.5% over six months and up 2.1% in 2026-to-date.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Broker Notes

What is Morgans saying about Cochlear and Northern Star shares?

Here's what the broker is saying about these big names following their updates.

Read more »

A woman with a mobile phone in her hand looks sceptical with a puzzled expression on her face with an eyebrow raised and pursed lips.
Broker Notes

Buy, hold, sell: NextDC, Hub24, PLS Group shares

The market is pessimistic about the next round of talks between the US and Iran.

Read more »

A team of people giving the thumbs up sign.
Broker Notes

5 ASX 200 shares with renewed buy ratings this week

Brokers have indicated continuing confidence in Cochlear, REA, and several other ASX 200 shares.

Read more »

Buy now written on a red key with a shopping trolley on an Apple keyboard.
Broker Notes

Broker reiterates buy ratings on 2 ASX shares

These ASX shares remain worth watching.

Read more »

Sell buy and hold on a digital screen with a man pointing at the sell square.
Broker Notes

After more than quadrupling investors' money in a year, are PLS shares still a buy?

A leading analyst delivers his outlook for the soaring PLS share price.

Read more »

A young man wearing a bright yellow jumper and glasses purses his lips together and moves them to the side of his face as he wonders about something.
Broker Notes

Buy, hold, or sell? Life360, Iress, Lynas Rare Earths shares

Experts reveal their views.

Read more »

Worried woman calculating domestic bills.
Broker Notes

Why did this broker just lower its outlook on this ASX 200 stock?

Despite a lowered outlook, attractive upside remains.

Read more »